Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Nolupus:
Thanks for your response. I agree that there might be some justification for the difference between the price of 180p in 2018 just before the result of the first Lupuzor Phase 3 trial, and the price now.
But what I find strange is the contrast between the SP of 48.5p in 2013 when I bought my first IMM shares and the price now. In 2013, Lupuzor was still some way from entering its Phase3 trial and IMM had no other drug candidate close to the same stage of development. This is in contrast to now. We have the P140 formulation to treat CIDP which is at the same advanced stage of FDA testing as Lupuzor. Plus there are the 2 other anti-infectives at an earlier stage of testing. Moreover, IMM now has a commercial partner, Avion, which is willing to commit to a much larger budget for the new Lupuzor trial. That advantage was not on the horizon for IMM in 2013. So how come its SP then, was 25 times higher than it is now? I still don't get it.
It's strange that 10 years ago, I paid 25 times what I'm paying now per IMM share. Can there be a rational justification for this huge difference?
Dallo/wildbunch
Your reference to being long term holders of IMM stock, made me look at my holdings. I found that my first purchase was on 13/8/2013, ie. more than a decade ago. I bought 10,000 @ 48.50.
I never thought then that I would have to wait and wait for so long before I knew whether this would turn out to be a wise investent or not. And I'm still none the wiser! But I've averaged down in the past 2 years and now into single figures, price-wise, but at the cost of even more exposure to this share.
Wildbunch:
I've been trying to guess what EMH stands for. I presume not ExtraMarital(H)affairs. Can you please explain to this ignoramus?
Wildbunch:
Your hypothesis is quite convincing.
Lisa has been urging me to be patient just as she is having to be patient with her team. At the same time she says that everyone is on the same page within IMM/Avion and know it is important to make an announcement to shareholders asap.
This does not suggest a crisis, let alone the likelihood that Avion is about to quit the deal. As you say, perhaps the opposite is the truth.
Nolupus:
Yes, how about the deal with Avion to finance the new Phase2/3 Lupuzor trial?
Llol:
That's no reply to Pokerchips. It's up to you to produce the evidence of Tim's false promises, not Poker's job to sieve through your many posts.
MM:
Good to hear that you are receiving excellent care from your health professionals. Good luck for the future.
Re IMM and Tim. How can you possibly tell whether he is taking private shareholders for a ride? How can you know whether Tim cares about shareholders and lupus sufferers? Perhaps he is powerless to dictate the pace at which the Avion and IMM research teams are working towards final agreement on the details of the Lupuzor trial. Give the guy a break and believe that he and other leaders of both companies are acting in good faith towards us and lupus sufferers. I'm just a private shareholder like you, but I accept the assurances from Lisa Baderoon, who liaises with people like us on behalf of IMM, that the research teams of both companies are working collaboratively to achieve the best outcome for Lupuzor in its final Phase 2/3 trial. There is very little that Tim can or should do in all this, except to update us on what is going on.
Mystic Mike:
I am really sorry to hear of your struggle with cancer. Please take comfort that there will be many on the platform who will join with me in wishing you all the best with your treatment and hoping that your treatment will return you to good health. Much more important than the share price of IMM. Naturally we all hope Lupuzor will turn out to be a success but it's not the be-all and end-all of life
Wildbunch:
I agree, it's much better to contact IMM directly than to indulge in histrionics like MysticMike and others of his ilk. I have always found that Lisa answers my queries within the boundaries that obviously stop her from revealing insider information. I believe that she is behaving in good faith when she says that the senior teams of IMM and Avion know the importance of bringing news to the public about Lupuzor and IMM's other drug candidates as soon as possible. The problem is that it takes more time to agree the details and protocols of the next Lupuzor Trial than I and obviously many other private investors had reckoned on.
My hope and expectation is that there will be a major announcement before Christmas.
Lambo222;
You are mistaken when you say of Avion and IMM ""they have never conducted trials before". Avion has considerable experience of bringing new drugs to market via FDA trials and IMM has the experience of its previous Phase 3 Lupuzor trial which failed but at least gave the company some insight into the likely pitfalls of any new trial they participate in. I suggest that the time it's taking to announce the start of the new Phase2/3 trial of Lupuzor is due to a desire to dot all the "i's" and cross every "t's" to ensure as far as possible that this time the Lupuzor trial will be successful.
But I presume that we'll all be a lot wiser shortly when IMM at last releases a new RNS on this.
Machin:
I would not say you are crazy. It all depends on whether you can afford to lose your investment. And tho' I sometimes feel depressed with the painfully slow progress being made in getting the Lupuzor Phase 2/3 Trial started and by the likewise slow progress on the CIDP trial and the ROW licence to develop Lupuzor, I still think that the purchase of IMM shares at the present cheap as chips price will come good, BIG time.
But I am getting tired of waiting!
Oscar:
It's 10 days since your interesting comments on the strategic alliance between Avion and IMM leading up to the next Lupuzor trial.
Tim McC has always promised that the next Lupuzor trial would would start in H2 of this year. We are now getting awfully close to the end of this period. In your opinion, are there any signs that his promise will be fulfilled?
Pokerchips:
I'm sure that Oscar can explain this better than I can. The upcoming Lupuzor trial is a collaboration between IMM and Avion in which the latter bears the cost of the trial and in return, Imm bestows on it the sole right to trade Lupuzor in North America. In the lead-up to the start of the trial, the scientists of the two companies are collaborating on the design and parameters of the trial.
In addition, if the trial is successful, Avion will pay IMM further fees based on FDA approval of Lupuzor and sales performance. So it is mistaken to call the new trial as belonging to Avion and entitling them to all the data that it accrues. It will be equally shared with IMM who will no doubt be in discussions with Avion throughout the trial.
Lordsloadsoflolly:
Let's not get bogged down by semantics. Oscar's analysis is 1. The time that it takes to get all the details of a successful Lupuzor trial is considerable. 2. The information, including from mistakes, that Avion and IMM have acquired in the past 4 years in dealing with earlier trials and with the FDA, is invaluable to ensuring the the forthcoming P2/3 trial will be as well constructed as possible. 3. This delay in the news flow should not be used for wild speculation. 4. It's a time for patience.
Oscar has also done us a service in explaining the Lanstead Share Agreements. I admit that I don't wholly understand them but it seems that Lanstead benefits whether the SP sinks or swims. It the price sinks during one month, they pay IMM less at the end of the month for the shares they have already pledged to buy. If the share price rises above an average of 2.64p in the month, at the end of that month, Lanstead pays more than it has pledged for that month's tranche of shares it has agreed to buy. But the base price used to calculate the excess they have to pay over the pledged amount is 30% over the price they have paid for the shares. And their entire share holding benefits from the increased share price. So they win both ways. They only lose if IMM not only sinks but capsizes. Why would they do that? Simple?
Anyway, oscar, you deserve an Oscar for your well informed contributions to this BB.
5RINGS; I would love you to be correct about Tim being about to announce fantastic news. But what evidence do you have? Is it just a gut feeling?
Draye:
I am unable to pontificate on the cause of the delay in announcing the start of the Lupuzor 2/3 Trial. I think it is hardly likely to have much to do with Tim McC being incompetent or not. I assumed that the recruitment of a CRO to conduct the trial would be mainly in the hands of Avion and that the selected CRO would be American. But I think we should be given guidance from IMM on why it is taking so long to move on to the next stage of the Lupuzor saga.
Willdbunch:
Your obversation that 3 CROs are being considered for the 2/3 Lupuzor Trial is more than I knew. Do you have any more information on how long the time frame is for making a decision on which of the three will be chosen? It seems to be taking an awfully long time.
MaverickD;
Thanks for your messaging. I think we are in on the same page. I feel particularly interested because some of my relatives suffer from auto-immune diseases such as Lupus, Crohns and Asthma.
In his latest interviews, Tim has held to H2 being the time frame for approval of the Lupuzor trial's design and approval, and for solid news on funding agreements with partners for CIDP and ROW Lupuzor. His credibility would be zero if Lupuzor Phase 2/3 Trial is not approved and if there is not substantial news on funding of CIDP, etc.
I am hopeful that at least some of his optimism will be justified.
Have just reached a million shares. Failure or fortune?